---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-043227"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:24:54.361872+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assertio completes sale of six product franchises to Cosette for $35M cash plus up to $35M contingent payments

## Summary
- Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.
- Upfront cash $35M; potential milestones up to $32M (SYMPAZAN, INDOCIN, OTREXUP) and SPRIX earn-out (quality approval $1M, 8% gross profits through 2027, $2M if 2027 net sales >$7M).
- Pro forma continuing ops: 2025 net loss ~$31.3M (historical $30.4M); 2024 net loss ~$27.5M (historical $21.6M).
- Estimated transaction costs ~$1.9M; estimated gain on disposal ~$16M.
- Company also divested Assertio Therapeutics in May 2025; results removed from continuing ops in pro forma.

## SEC filing metadata
- accession: 0001104659-26-043227
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/0001104659-26-043227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/tm2611405d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-043227
- JSON: https://secwatch.observer/filing/0001104659-26-043227.json
- Plain text: https://secwatch.observer/filing/0001104659-26-043227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.